Document ID: chunk:federal_register_of_legislation:F2024L01748:front:0:p2
Version: federal_register_of_legislation:F2024L01748
Segment Type: other
Provision Reference: 
Character Range: 3341–6277

Act means the National Health Act 1953.

Part 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day

6 Weighted average disclosed price for brands of pharmaceutical items in Schedule 1

      (a) For subsection 99ADB(4) of the Act, the weighted average disclosed price of a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 1 is the amount specified in column 3 of that table item.

      (b) Subsection (a) applies in respect of a data collection period for a brand of pharmaceutical item ending on 30 September 2024.

           Note: Paragraph 99ADH(1)(a) of the Act applies if, under section 99ADB, the Minister determines the weighted average disclosed price of a brand of a pharmaceutical item in respect of a data collection period for the brand.

7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items

      The adjusted approved ex-manufacturer price of a brand of pharmaceutical item specified in column 2 of the table to Schedule 1 is the amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 6 of this instrument.

           Note: Subsection 99ADB(7) of the Act provides that a determination made under subsection 99ADB(4) in relation to a brand of pharmaceutical item may include the adjusted approved ex-manufacturer price of the brand of pharmaceutical item.

8 Reduction Day

      For paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 1 has a reduction day of 1 April 2025.

Part 2 – Brands of pharmaceutical items with a weighted average disclosed price

9 Weighted average disclosed price for brands of pharmaceutical items in Schedule 2

      (a) For subsection 99ADB(4) of the Act, the weighted average disclosed price of a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 2 is the amount specified in column 3 of that table item.

      (b) Subsection (a) applies in respect of a data collection period for a brand of pharmaceutical item ending on 30 September 2024.

      Note:  This instrument does not determine a reduction day for paragraph 99ADH(1)(aa) of the Act for a brand

Schedule 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted ex-manufacturer price and reduction day

Column 1  Column 2                                         Column 3
          Brand of Pharmaceutical Item
Item      Listed Drug                                      Form                                                                                                                                                                                      Manner of administration  Brand                                            Weighted average disclosed price